Key facts, as of
As of November 4, 2026, Regeneron Pharmaceuticals (REGN) trades at $949.76, up 51.2% over the past year. Its 52-week range runs from $591.52 to $991.73; the price is 4.2% below that high. It is 21.6% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +171.5%, against +316.3% for the S&P 500 (SPY). It sits 28.2% above its 200-day average of $740.91, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 49.0% annualized, which we rate high risk. It has a trailing P/E of 21.0 and a dividend yield of 0.39%.
Cite: Portfolio Terminal, "Regeneron Pharmaceuticals (REGN) stock analysis", 2026-11-04. https://portfolio-terminal.com/analyse/regn
Where it trades today
trading 90% of the way up its 52-week range
How the price has moved
How far it is from its record
Regeneron Pharmaceuticals (REGN) is 21.6% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +171.5%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- REGN closes above its 50-day average ($801.07), and the 50-day sits above the 200-day ($740.91): on both averages the chart reads as an uptrend.
- At $949.76, REGN is 4.2% below its 1-year high of $991.73, set on November 4, 2026, and 60.6% above its 1-year low of $591.52 (June 2, 2026).
- Over the past month REGN rose 30.7%, from $726.47 to $949.76.
- REGN trades at 21.0x its last twelve months of earnings and 13.4x the next twelve months' estimate, so analysts expect earnings 56.3% higher.
- Its P/E is 56.5% below the 48.3x median of the 2 other biotechnology companies we track (VRTX, INCY).
- REGN's 30-day volatility, 49.0% a year, works out to a typical daily move of about 3.1%.
- Yahoo Finance puts its beta at 0.10: over five years of monthly returns, REGN moved about 0.10% for each 1% move of the S&P 500.
- The last session traded 0.4x REGN's average daily volume of the 30 sessions before it.
What would change the read
- A close under the 50-day average, $801.07 (−15.7% from the last close), would turn the read to a pullback; under the 200-day, $740.91 (−22.0%), the longer rise is in question.
- A close above $991.73 (+4.4%) would be a new 1-year high; below $591.52 (−37.7%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for REGN, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under biotechnology among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for REGN by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for REGN. Last refresh: Nov 4, 2026, 3:42 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Biotechnology.
What Regeneron Pharmaceuticals does
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent…
What analysts expect
REGN carries a buy consensus from 27 analysts, with an average price target of $977.93 versus $949.76 today (+3.0%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
REGN generated $16.90B in trailing revenue (36.3% year over year), with a 28.5% net margin, and $2.58B of free cash flow, supported by $6.59B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $14.34B | $12.24B | $3.70B | $4.50B | $43.07 | $3.77B |
| 2024 | $14.20B | $12.23B | $3.99B | $4.41B | $40.90 | $3.54B |
| 2023 | $13.12B | $11.30B | $4.05B | $3.95B | $37.05 | $3.67B |
| 2022 | $12.17B | $10.61B | $4.74B | $4.34B | $40.51 | $3.40B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
REGN is in 20 of the 54 ETFs we track. It weighs most in XLV: 1.21% of the fund, holding #22 of 62.
Famous investors who hold it
REGN is in the latest 13F of 2 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.13% of the portfolio, position #124 of 992, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
REGN beside the other companies Yahoo Finance files under biotechnology among the assets we track (VRTX, MRNA, INCY, largest first).
REGNyou are here$949.76$98.25B
VRTXVertex Pharmaceuticals$534.86$135.57B
MRNAModerna Inc.$248.36$99.15B
INCYIncyte Corporation$118.97$24.25BWhat the chart is saying
In an uptrend, 4.2% under its 1-year high with no resistance above.
uptrend- Price is 18.6% above its 50-day average and 28.2% above its 200-day.
- The 50-day crossed above the 200-day on 2026-09-03 (a “golden cross”).
- RSI at 75 is overbought: strong momentum, and stretched.
- Nothing above has stopped it this year; the nearest floor is $853.17 (-10.2%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is REGN valued right now?
Regeneron Pharmaceuticals trades at 21.0 times its last twelve months of earnings and 13.4 times the next twelve months' estimate (Yahoo Finance, November 4, 2026). On the chart: in an uptrend, 4.2% under its 1-year high with no resistance above. Price is 18.6% above its 50-day average and 28.2% above its 200-day.
What is the risk level of REGN?
Based on 30-day volatility of 49.0%, REGN has HIGH risk. Its beta of 0.10 means it has swung less than the S&P 500 over the last five years.
Does REGN pay dividends?
Yes, Regeneron Pharmaceuticals has a dividend yield of 0.39%.
How far is REGN from its all-time high?
Regeneron Pharmaceuticals is 21.6% below its all-time high of $1,211.20, reached in August 2024. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +171.5%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold REGN?
20 of the 54 popular ETFs we track hold Regeneron Pharmaceuticals. The largest weights: XLV (1.21%), JEPI (0.99%), JEPQ (0.49%), VO (0.38%) and CNDX (0.35%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is REGN?
0.11%, as of September 30, 2026: REGN is holding #151 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $1.13 in Regeneron Pharmaceuticals.
Which famous investors own REGN?
Ray Dalio (0.13% of Bridgewater Associates's 13F) and Renaissance Technologies (0.13% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for REGN?
The average analyst price target for Regeneron Pharmaceuticals (REGN) is $977.93 based on 27 analyst estimates, about 3.0% above the current price of $949.76. The published range runs from $812.00 to $1175.00.
How much revenue does REGN generate?
Regeneron Pharmaceuticals reported $16.90B in trailing twelve-month revenue. Revenue growth is running at 36.3% year over year. Net margin sits at 28.5%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare REGN with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.